N/A N=108 Pruritus in Patients With Chronic Kidney Disease
Kidney Failure, Chronic · Pruritus
Primary: Visual Analog Scale (VAS) — 3.35 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
Uremic Pruritus
Primary: Visual Analogue Scale (VAS) Score for Pruritus — -3.38; -3.53 Units on a scale — p=<0.05
Phase 2 N=269 A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Chronic Kidney Diseases · Pruritus
Primary: Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score During Week 12 — -3.99; -3.84; -4.42; -3.32 score on…
Phase 2 N=111 The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial
Chronic Kidney Disease-associated Pruritus
Primary: Mean Change in Weekly Mean Worst Itch Numeric Rating Score (WI-NRS) — -3.70; -3.87 score on a scale
Phase 3 N=258 To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Primary: Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12 — 38.5; 47.7; 32.4…
Phase 4 N=50 A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients
Pruritis
Primary: Severity of Pruritis — 10.88; 9.76; 6.64; 5.12 units on a scale
Phase 3 N=175 Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Change From Baseline in the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score During Week 8 — -3.8; -2.8; -3.2; -1.9 score on a scale — p=<0.001
Phase 2 N=247 A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Uremic Pruritus
Primary: Change From Baseline in the Mean NRS Score at Week 8 of the Treatment Period — -2.97; -3.65; -3.64; -2.86 points — p=0.770
Phase 3 N=222 CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Number of Participants With AEs. — 143 Participants
Phase 3 N=178 A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Uremic Pruritus
Primary: Change From Baseline in the Mean NRS Score at Week 4 — -2.06; -1.09 points — p=<0.001
Phase 3 N=378 A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
Uremic Pruritus
Primary: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily…
Phase 3 N=373 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Uremic Pruritus · Pruritus
Primary: Change From Baseline to the Evaluation Period in Itch on the 0-10 Itch Numerical Rating Scale — -3.10; -3.49; -2.80 units on a scale
Phase 2 N=58 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Chronic Idiopathic Urticaria · Chronic Idiopathic Pruritus · Lichen Planus
Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980
N/A N=60 Evaluation of the Efficacy of Laser Acupuncture on Uremic Pruritus
Uremia
Primary: Title: Evaluation of the Efficacy of Laser Acupuncture on Ureimc Pruritus — 18.13; 17.47; 10.20; 17.10 points — p=<0.05
Phase 3 N=288 Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Number of Participants With AEs — 240 Participants
Phase 2 N=9 Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Pruritus
Primary: Change in Peak Pruritus Numerical Rating Score (PRNS) — -3.1 score on a scale
Phase 3 N=471 CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily…
Phase 4 N=28 Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients
Pruritis
Primary: Investigator Global Assessment — 2.63; 2.32 units on a scale
Phase 3 N=260 Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Change From Baseline in the Weekly Mean of the Daily 24-hour WI-NRS Score at Week 4 of the DB Period — -2.09; -1.27 score on a scale — p=0.0003
Phase 2 N=10 A Study Examining the Medication Apremilast as Treatment for Chronic Itch
Itch
Primary: Absolute NRS Itch Score at Week 16 (End of Treatment) — 7; 7.5 Units on a scale
Phase 2 N=20 Topical Aprepitant in Prurigo Patients
Pruritus
Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58
Phase 2 N=233 Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Pruritus
Primary: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10 — 46; 44 Participants — p=0.5861
N/A N=14 Chronic Kidney Disease Among Frail Elderly
Chronic Kidney Disease
Primary: Mortality — 0; 0 percentage of mortality
N/A N=781 Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study
Chronic Renal Insufficiency
Primary: PTH (Parathyroid Hormone) Adherence — 0.23; 0.28 probability of having a PTH measured — p=0.04
Phase 1 N=11 Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants
Phase 3 N=167 Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Uremic Pruritus · Pruritus
Primary: Number and Percetage of Participants With Treatment Emergent Adverse Events (TEAEs) — 133 Participants
Phase 1 N=40 Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
Pruritus · Cholestasis · Kidney Failure
Primary: Incidence of Adverse Events — 5; 5; 5; 3 participants
Phase 2 N=20 Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
Prurigo Nodularis · Pruritus · Chronic Pruritus
Primary: Percent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12 — -78.26; -53.66 percent change — p=<0.001
N/A N=6,295 Chronic Kidney Disease Clinical Decision Support
Chronic Kidney Diseases · Hypertension · Diabetes
Primary: Number of Participants With CKD Diagnosis — 417; 389 Participants — p=.21
Phase 2 N=54 Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients
Secondary Hyperparathyroidism · Chronic Renal Insufficiency
Primary: Reduction in Mean iPTH of ≥ 30% During the Efficacy Assessment Phase — 15; 5 Participants — p=0.006